Scientists offer new clues as to how overzealous neuronal firing may fuel synaptic loss in early Alzheimer's. In Science July 9, scientists led by Soyon Hong at University College London report that ...

Could measuring proteins in the blood help pinpoint which genes underlie certain GWAS signals? By combining plasma proteomics data with genetic analyses, scientists led by Keenan Walker at the ...

In the quest to understand how APOE4 heightens the risk of Alzheimer’s disease, scientists are drilling down to nuances such as how the variant acts in women versus men, and how it affects cell types.

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

Scientists discussed anti-Aβ therapeutic antibodies, confirming their ability to remove brain amyloid and working to boost their brain exposure. They continued their postmortem of BACE inhibitors in ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

Intepirdine failed in Phase 3. The drug did not improve cognition or activities of daily living in patients with mild to moderate AD. News of the failure sent Axovant’s share price plunging. Axovant’s ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Among the assorted communities of brain cells contained within an 8 millimeter punch of cortex, scientists have captured what might reflect two pivotal microglial moments along the decades-long ...